Role of Bosentan in Interstitial Lung Disease
Bosentan should NOT be used for the treatment of pulmonary hypertension in patients with interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF), as it has failed to demonstrate benefit in mortality, disease progression, or functional outcomes in this population.
Evidence-Based Recommendation
The most definitive evidence comes from the 2015 ATS/ERS/JRS/ALAT guideline 1, which specifically addresses endothelin receptor antagonists in IPF. Two major randomized controlled trials (BUILD-1 and BUILD-3) evaluated bosentan in IPF patients:
Key Trial Results:
BUILD-1 (n=158):
- No mortality benefit (RR 1.14; 95% CI 0.24-5.54)
- No significant improvement in disease progression
- No differences in FVC, quality of life, or dyspnea scores 1
BUILD-3 (n=616, biopsy-proven UIP):
- No mortality benefit (RR 1.25; 95% CI 0.53-2.96)
- No effect on disease progression (RR 0.86; 95% CI 0.71-1.05)
- No improvements in any secondary outcomes 1
Critical Distinction: ILD vs. PAH
The confusion around bosentan's role stems from its proven efficacy in primary pulmonary arterial hypertension (PAH), where it has Grade A evidence 2, 3. However, pulmonary hypertension secondary to ILD represents a fundamentally different pathophysiology (WHO Group 3 vs. Group 1).
When Bosentan IS Indicated:
- Primary PAH (WHO Functional Class III): Grade A recommendation 2
- PAH associated with connective tissue disease: Established benefit 3
- Dosing: 62.5 mg twice daily for 4 weeks, then 125 mg twice daily 4
When Bosentan is NOT Indicated:
- ILD with secondary pulmonary hypertension: The 2011 ATS/ERS guideline explicitly states pulmonary hypertension should NOT be treated in the majority of IPF patients (weak recommendation against) 5
- The 2009 ACCF/AHA consensus document notes that "the role of PAH-specific therapies in the treatment of PH associated with ILD has not been adequately investigated" 6
Clinical Algorithm for Decision-Making
Step 1: Identify the Primary Disease Process
- Is this primary PAH (idiopathic, heritable, drug-induced)?
- Or is this PH secondary to parenchymal lung disease (ILD/IPF)?
Step 2: If ILD is Present:
- Optimize treatment of underlying ILD first
- Provide supplemental oxygen 6
- Do NOT initiate bosentan for the PH component
Step 3: Exception Consideration (Controversial)
- Only in patients with severe PH documented by right heart catheterization (mean PAP >35 mmHg) AND predominantly vascular disease (not parenchymal), a trial of vasomodulatory therapy may be considered 5
- This represents a minority exception, not standard practice
Important Caveats
Safety Monitoring Required:
If bosentan is used (in appropriate PAH patients, not ILD):
- Monthly liver function tests mandatory - hepatic aminotransferase elevations occur in ~10% of patients 4
- Dose-dependent and reversible with reduction or discontinuation 3
- Monitor hemoglobin levels (reductions can occur) 4
Risk of Harm in ILD:
- Potential for worsening V/Q mismatch leading to hypoxemia due to nonselective vasodilation 6
- Cost burden without demonstrated benefit
- Drug-related adverse effects without offsetting efficacy 1
Contradictory Observational Data:
While small observational studies 7, 8 and recent retrospective reviews 9 suggest potential benefit, these are superseded by the negative randomized controlled trial data 1. The guideline appropriately prioritizes RCT evidence over case series when making treatment recommendations.
Bottom Line
For ILD/IPF patients with secondary pulmonary hypertension: Focus on treating the underlying lung disease and providing supportive care (oxygen, diuretics if needed). Do not use bosentan. The evidence is clear that bosentan does not improve outcomes in this population and may cause harm through adverse effects and cost without benefit 5, 1.
For primary PAH (WHO Group 1): Bosentan remains a cornerstone therapy with Grade A evidence 2, 3, 4.